{"id":158088,"date":"2017-12-19T18:02:41","date_gmt":"2017-12-19T10:02:41","guid":{"rendered":"https:\/\/www.medl10n.com\/wp-content\/uploads\/dlm_uploads\/2017\/12\/CFDA-White-Paper-Reform-EN-MedL10N.pdf"},"modified":"2017-12-19T18:02:41","modified_gmt":"2017-12-19T10:02:41","slug":"cfda-white-paper-reform-en-medl10n-4-2","status":"inherit","type":"attachment","link":"https:\/\/lifesciences.csoftintl.com\/zh-hans\/?attachment_id=158088","title":{"rendered":"CFDA White Paper Reform EN-CSOFT Health Sciences"},"author":3,"comment_status":"open","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false},"aioseo_notices":[],"description":{"rendered":"

CFDA White Paper Reform EN-CSOFT Health Sciences<\/a><\/p>\n

Since 2015, the CFDA has initiated a series of reform documents, with the purpose of pushing the Chinese pharmaceutical and medical device industry to a more mature and globalized environment.<\/p>\n"},"caption":{"rendered":"

Since 2015, the CFDA has initiated a series of reform documents, with the purpose of pushing the Chinese pharmaceutical and medical device industry to a more mature and globalized environment.<\/p>\n"},"alt_text":"","media_type":"file","mime_type":"application\/pdf","media_details":{},"post":128146,"source_url":"https:\/\/lifesciences.csoftintl.com\/wp-content\/uploads\/dlm_uploads\/2017\/12\/CFDA-White-Paper-Reform-EN-MedL10N.pdf","_links":{"self":[{"href":"https:\/\/lifesciences.csoftintl.com\/zh-hans\/wp-json\/wp\/v2\/media\/158088"}],"collection":[{"href":"https:\/\/lifesciences.csoftintl.com\/zh-hans\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/lifesciences.csoftintl.com\/zh-hans\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/lifesciences.csoftintl.com\/zh-hans\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/lifesciences.csoftintl.com\/zh-hans\/wp-json\/wp\/v2\/comments?post=158088"}]}}